Labcorp
About: Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Employees: 70,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
29% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 9 (+2) [Q4]
20% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 90
6% more capital invested
Capital invested by funds: $16.8B [Q3] → $17.8B (+$1.06B) [Q4]
3.4% more ownership
Funds ownership: 89.6% [Q3] → 93.0% (+3.4%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 334 | Existing positions reduced: 333
0% less funds holding
Funds holding: 907 [Q3] → 905 (-2) [Q4]
29% less call options, than puts
Call options by funds: $48.5M | Put options by funds: $68.4M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$250
4%
upside
Avg. target
$274
14%
upside
High target
$300
24%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Barclays Jack Meehan 0 / 0 met price target | 4%upside $250 | Equal-Weight Maintained | 30 Apr 2025 |
Baird Eric Coldwell 45% 1-year accuracy 14 / 31 met price target | 11%upside $267 | Outperform Maintained | 30 Apr 2025 |
Truist Securities David Macdonald 54% 1-year accuracy 55 / 101 met price target | 14%upside $274 | Buy Maintained | 11 Apr 2025 |
Redburn Atlantic Jamie Clark 50% 1-year accuracy 2 / 4 met price target | 15%upside $276 | Buy Initiated | 2 Apr 2025 |
Citigroup Ralph Giacobbe 0% 1-year accuracy 0 / 1 met price target | 24%upside $300 | Buy Upgraded | 4 Mar 2025 |
Financial journalist opinion
Based on 16 articles about LH published over the past 30 days
Neutral
Seeking Alpha
1 day ago
Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Christin O'Donnell - Investor Relations Adam Schechter - Chairman & Chief Executive Officer Julia Wang - Executive Vice President & Chief Financial Officer Conference Call Participants Michael Cherny - Leerink Partners Ann Hynes - Mizuho Securities Erin Wright - Morgan Stanley Elizabeth Anderson - Evercore ISI Lisa Gill - JPMorgan Jack Meehan - Nephron Research Luke Sergott - Barclays Kevin Caliendo - UBS Michael Ryskin - Bank of America Patrick Donnelly - Citi Eric Coldwell - Baird Kieran Ryan - Deutsche Bank Operator Good day and thank you for standing by. Welcome to the Q1 2025 Labcorp Holdings Earnings Conference Call.
Positive
Zacks Investment Research
1 day ago
Labcorp (LH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
1 day ago
Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains
LH delivers better-than-expected earnings in the first quarter of 2025.
Positive
Zacks Investment Research
1 day ago
Labcorp (LH) Beats Q1 Earnings Estimates
Labcorp (LH) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.68 per share a year ago.
Positive
Reuters
1 day ago
Labcorp beats quarterly profit estimate on diagnostic test demand
Laboratory operator Labcorp beat analysts' estimate for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.
Neutral
PRNewsWire
1 day ago
Labcorp Announces 2025 First Quarter Results
Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion to $1.25 billion Providing broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-date Introduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid in the diagnosis of Alzheimer's disease BURLINGTON, N.C. , April 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance.
Neutral
PRNewsWire
1 week ago
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.
Neutral
Zacks Investment Research
1 week ago
Labcorp (LH) Earnings Expected to Grow: Should You Buy?
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
2 weeks ago
Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth
LH's first-quarter 2025 performance is likely to have benefited from both its Dx and BLS businesses.
Neutral
GlobeNewsWire
2 weeks ago
Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics
Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The market for genetic screening testing in preventive health has been experiencing rapid growth, driven by driving factors such as technological advancements, increased consumer interest in personalized medicine, and the rise of preventive healthcare strategies. Several key factors influence the expansion of the genetic screening testing for preventive health market. Improvements in genetic testing technologies, such as next-generation sequencing (NGS), have made these tests more accessible, cost-effective, and accurate. Growing consumer awareness of the benefits of early detection, rising healthcare costs, and an increasing focus on prevention have further fuelled the demand. Moreover, the increasing availability of direct-to-consumer genetic tests has allowed individuals to manage their health. Stakeholders in this market include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness-focused organizations. As more people seek personalized, data-driven approaches to healthcare, the demand for genetic screenings as a preventive tool is expected to increase. Moreover, the growing availability of direct-to-consumer genetic testing kits has empowered individuals to take charge of their health and gain insights into their genetic predispositions without necessarily needing a healthcare provider. This trend has significantly expanded the genetic screening market, allowing consumers to access preventive health information more easily. The genetic screening testing for preventive health market is set to witness substantial growth. With continued technological advancements and growing public interest in health optimization and disease prevention, the market offers significant opportunities for healthcare, biotechnology, and wellness stakeholders to meet the rising demand for personalized, proactive health solutions. The development of next-generation sequencing (NGS) technologies and improvements in bioinformatics have made genetic testing more accurate, efficient, and affordable. These innovations allow for comprehensive genetic analysis, enhancing the ability to detect predispositions to various diseases at earlier stages. The continuous evolution of these technologies further drives the demand for genetic screening services in preventive healthcare. Furthermore, there is a growing recognition of the importance of preventive healthcare, with more individuals understanding the benefits of early disease detection and management. Public health campaigns, medical professionals, and organizations have been emphasizing the value of genetic screening to detect health risks before symptoms appear, further driving market demand.
Charts implemented using Lightweight Charts™